Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. Show more

Location: 201 Brookline Avenue, Boston, MA, 02215, United States | Website: https://www.tangotx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.036B

52 Wk Range

$1.03 - $9.70

Previous Close

$7.79

Open

$7.78

Volume

5,466,572

Day Range

$7.57 - $8.25

Enterprise Value

709.8M

Cash

180.8M

Avg Qtr Burn

-37.06M

Insider Ownership

4.98%

Institutional Own.

92.00%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.